Rollover Study of BMS-354825 in Patients With CML and Ph+ALL

NCT01030718 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myelogenous Leukemia
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Interventions

DRUG: dasatinib

Sponsor

Bristol-Myers Squibb